Brian Munansangu is a postdoctoral researcher who is comfortable explaining T-cell activation and immunometabolism to scientists.
Then he went home to Zambia for Christmas. Around a fire in his aunt’s village, she asked him whether the new HIV prevention injection, lenacapavir (LEN), could cure HIV.
She has lived with HIV for years. She faithfully takes her treatment. She attends her clinic appointments. Yet she’s confused about what LEN is — …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.